21 – 30 of 37
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2012
-
Mark
Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.
(
- Contribution to journal › Article
- 2011
-
Mark
Stromal Expression of β-Arrestin-1 Predicts Clinical Outcome and Tamoxifen Response in Breast Cancer.
(
- Contribution to journal › Article
-
Mark
PKA-induced phosphorylation of ER alpha at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer
(
- Contribution to journal › Article
- 2010
-
Mark
Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
(
- Contribution to journal › Article
-
Mark
17 beta-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer
(
- Contribution to journal › Article
-
Mark
p27(Kip1) is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients.
(
- Contribution to journal › Article
- 2009
-
Mark
Estrogen Receptor-{alpha} Phosphorylation at Serine-118 and Tamoxifen Response in Breast Cancer.
(
- Contribution to journal › Article
-
Mark
Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.
2009) In Modern Pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 22. p.1564-1574(
- Contribution to journal › Article
- 2008
-
Mark
HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
(
- Contribution to journal › Article
-
Mark
Exploring the two-gene ratio in breast cancer-independent roles for HOXB13 and IL17BR in prediction of clinical outcome
(
- Contribution to journal › Article